ERBB2 and breast cancer: In addition, given the possible sub-optimality of the IHC/ISH-based method in the detection of HER2-low breast cancer patients, alternative technologies for a quantitative evaluation of HER2 have been suggested as potentially capable of improving our ability to identify this emerging breast cancer subset34–39, however none of them have yet been formally validated.